Title: Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
Authors: Sch√∂ffski, Patrick ×
Besse, B
Gauler, T
de Jonge, M J A
Scambia, G
Santoro, A
Davite, C
Jannuzzo, M G
Petroccione, A
Delord, J-P #
Issue Date: Mar-2015
Publisher: Kluwer Academic Publishers
Series Title: Annals of Oncology vol:26 issue:3 pages:598-607
Article number: 10.1093/annonc/mdu566
Abstract: This multi-centre phase II trial assessed the activity, safety (CTCAE 3.0) and pharmacokinetics (PK) of the pan-Aurora kinase inhibitor danusertib hydrochloride (PHA-739358) in breast (BC), ovarian (OC), pancreatic (PC), colorectal (CRC), small-cell (SCLC) and non-small-cell lung (NSCLC) cancers.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Efficacy and safety of biweekly iv adm of the Aurora kinase inhibitor danusertib hydrochloride in adv met BREA, ovarian etc_Annals of Onc.pdf Published 162KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science